Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 205

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 205
---
            |
| Criterion 6:held office for > 12 years                                                    | l              | l           | l                    | l               | l           | l              | l          | l               | l            | l                | l                     | l                     | l          | l           | l            |
| Criterion 7:non-executive director inreceipt of variable orperformance-linkedcompensation | l              | l           | l                    | l               | l           | l              | l          | l               | l            | l                | l                     | l                     | l          | l           | l            |
| Criterion 8:significant shareholder                                                       | l              | l           | X                    | l               | l           | l              | l          | l               | l            | X                | l                     | l                     | l          | l           | l            |
| Deemed independent                                                                        | YES            | NO          | NO                   | YES             | YES         | YES            | YES        | YES             | YES          | NO               | YES                   | YES                   | YES        | YES         | YES          |

l Independence criterion met X Independence criterion not met (a) This table only refers to independence as defined under the AFEP-MEDEF Code. However, Christophe Babule is independent for the purposes of the NASDAQ Listing Rules and Rule 10A-3 under the Exchange Act.

| 100 | SANOFIFORM 20-F2024 |

| PART I                                             |
| ITEM 6. Directors, Senior Management and Employees |

Failure to fulfil one of the criteria does not automatically disqualify a director from being independent. In assessing the criterion related to significant business relationships (criterion 3), the Board of Directors took into account the various relationships between directors and Sanofi and concluded that there was no relationship of a kind that might undermine their independence. The Board of Directors noted that the Company and its subsidiaries had, in the normal course of business, over the past three years, sold products and provided services to, and/or purchased products and received services from, companies in which certain of the Company's directors, who are classified as independent (or their close family members) were senior executives or employees during 2024. In each case, the amounts paid to or received from such companies over the past three years were determined on an arm's length basis and not at amounts that the Board regarded as undermining the independence of the directors in question. Selection process for Board members The Appointments, Governance and